Clinical trial
N99-02: Melphalan and Buthionine Sulfoximine
NCT00005835 · New Approaches to Neuroblastoma Therapy Consortium, Other · Completed
Key facts
| NCT number | NCT00005835 |
|---|---|
| Title | N99-02: Melphalan and Buthionine Sulfoximine |
| Official title | Modulation of Intensive Melphalan (L-PAM) by Buthionine Sulfoximine (BSO) Autologous Stem Cell Support for Resistant or Recurrent High-Risk Neuroblastoma (IND 69-112) |
| Acronym | BSO |
| Lead sponsor | New Approaches to Neuroblastoma Therapy Consortium, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Neuroblastoma |
| Intervention type | Drug, Other, Procedure |
| Interventions | buthionine sulfoximine, melphalan, Peripheral blood stem cell infusion, Filgrastim |
| Enrollment | 31 |
| Start date | Aug 1, 2001 |
| Primary completion | Dec 1, 2014 |
| Completion | Apr 1, 2016 |
| First posted | Jan 27, 2003 |
| Last update posted | Apr 10, 2023 |
| Countries | Canada, United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: